Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label single-arm zanidatamab study in HER2-positive salivary gland carcinoma
KCT0008350Phase 2Active, not recruiting
- Sponsor
- BeiGene
- Start
- Nov 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanidatamab in salivary gland cancer (SGC), sponsored by BeiGene. Primary endpoint: Objective response rate. Started Nov 2023; status: active, not recruiting.
02
Drugs
zanidatamab
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on KCT0008350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008350.